Safety, pharmacokinetics, pharmacogenomics and QT concentration−effect modelling of the SirT1 inhibitor selisistat in healthy volunteers

A potent and selective Sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington's disease

(2014) Marianne R. Smith et al.   HUMAN MOLECULAR GENETICS

The IQ-CSRC Prospective Clinical Phase 1 Study: “Can Early QT Assessment Using Exposure Response Analysis Replace the Thorough QT Study?”

(2013) Borje Darpo et al.   ANNALS OF NONINVASIVE ELECTROCARDIOLOGY

Early QT assessment - how can our confidence in the data be improved?

(2012) Borje Darpo et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Acetylation Targets Mutant Huntingtin to Autophagosomes for Degradation

(2009) Hyunkyung Jeong et al.   CELL

Is a Thorough QTc Study Necessary? The Role of Modeling and Simulation in Evaluating the QTc Prolongation Potential of Drugs

(2009) Shashank Rohatagi et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington’s disease

(2008) Judit Pallos et al.   HUMAN MOLECULAR GENETICS